Emanuel Petricoin

Dr. Petricoin is one of the inventors of the Nanotrap® technology and a renowned innovator in the field of proteomics and personalized medicine. As a founder of Ceres Nanosciences and Chief Scientist, Dr. Petricoin provides technical guidance and expertise to key components of Ceres Nanosciences' scientific research, product development, and industry collaborations.

Dr. Petricoin is a professor of Life Sciences and serves as the Co-Director of CAPMM Labs at George Mason University. Prior to this, Dr. Petricoin was the Co-Director of the FDA-NCI Clinical Proteomics Program, and a Senior Investigator within the Center for Biologics Evaluation and Research at the US Food and Drug Administration. He is a co-inventor on 40 filed and published patents, and has authored over 300 peer-reviewed publications and invited reviews. He has authored over 40 book chapters, is the Co-Editor-in-Chief of Human Genomics and Proteomics, is on the editorial board of Proteomics, Biomedical Microdevices, Proteomics- Clinical Applications, Proteomics- Protocols, Molecular Carcinogenesis, Journal of Personalized Medicine and is a Senior Editor for Cancer Epidemiology Biomarkers and Prevention. He was previously the founding Co-Editor-in-Chief of Clinical Proteomics. Dr. Petricoin is a founding member of the Human Proteomic Organization (HUPO) and US HUPO; he served on the Executive Committee of HUPO and as Treasurer from 2002-2004. He is a member of the Faculty of 1000. He has received numerous awards including the University Professorship at George Mason University, the NIH Director’s Award, FDA Distinguished Scientist Award, American Society of Cytopathology Basic Research Award, the Roche Diagnostics/CLAS Distinguished Scientist Award and the Harvard University Leading Edge Award.

Dr. Petricoin holds a Ph.D. in microbiology from the University of Maryland at College Park.